AK 002Alternative Names: AK 002
Latest Information Update: 05 Dec 2016
At a glance
- Originator Johns Hopkins University School of Medicine
- Developer Allakos
- Class Antibodies; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Mast cell inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Systemic mastocytosis
- Preclinical Fibrosis